24 Roy Street
Seattle, WA 98109
Complete this contact form for media, investor relations and partnership/business development inquiries
Please leave this field empty.
* required fields
A Feasibility Study of the EMulate Therapeutics Voyager System in Patients with Recurrent Glioblastoma Multiforme (rGBM). This study is currently recruiting qualified patients.
Abstract presented by Xavier Figueroa, PhD, at Society for Neuro-Oncology 2016 Annual Conference, Scottsdale, AZ on November 19, 2016.
The latest information on publications highlighting EMulate Therapeutics research and advancements.
November 29, 2021
Hapbee Announces Initial Closing of Upsized Non-Brokered Private Placement of $6.1 Million
November 17, 2021
EMulate Therapeutics Announces the Incorporation of Two Wholly Owned Subsidiaries
November 3, 2021
Hapbee Technologies Inc. Virtually Opens the Market
EMulate Therapeutics Voyager® ulRFE® System for rGBM is an investigational medical device. Limited by United States law to investigational use only.
© EMulate Therapeutics 2022. All rights reserved.